Gilead Sciences and Trianni announced that the companies have entered into a license agreement that grants Gilead the use of the Trianni transgenic human monoclonal antibody discovery platform to support the company’s drug discovery efforts. “We look forward to integrating Trianni’s technology into our research and development program,” said Bill Lee, PhD, Executive Vice President of Research, Gilead. “This platform will help enhance our ability to discover human antibodies and to develop new therapies in areas of unmet medical need.” No financial details were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.